A Tough Start to a New Decade

LPISM staff assembled for a group photo.  To Pauling's right are Emile Zuckerkandl, Ewan Cameron and Richard Hicks.

LPISM staff assembled for a group photo. To Pauling’s right are Emile Zuckerkandl, Ewan Cameron and Richard Hicks. By 1992, none of these three crucial staff members would remain affiliated with the Institute.

[A history of the Linus Pauling Institute of Science and Medicine, Part 5 of 8]

For the Linus Pauling Institute of Science and Medicine, the difficult decade of the 1980s was one plagued by lawsuits, dramatic monetary problems, and the death of Ava Helen Pauling. Yet for all of its struggles, LPISM soldiered on as best as it could.

One who would help define the decade to come, Dr. Matthias Rath, was a charismatic, intelligent, young German physician who had a passion for vitamin C and cardiovascular health. He had met Linus Pauling on numerous occasions, and in 1989 Pauling invited him to join the LPISM staff. Rath was charming and popular with many of his colleagues. However Pauling’s oldest son, Linus Jr. – a long-time Institute board member – took caution, noting in a 2012 interview his concern that Pauling would offer a position of importance to somebody that he felt was very inexperienced.

Two other major events occurred in 1990: Pauling and Zelek Herman developed a new method to analyze clinical trial data, and the National Cancer Institute installed a new president by the name of Samuel Broder. Pauling immediately began corresponding with Broder, and eventually convinced him to reopen the case for vitamin C as a treatment and prevention for cancer. This resulted in an international conference held in Washington D.C. in 1991 and sponsored by the NCI. It was titled “Ascorbic Acid: Biological Functions in Relations to Cancer.” Pauling was the obvious candidate for keynote speaker and he later said of the conference, “It was great! A great affair! Very exciting!”

Participants in the NCI symposium on Vitamin C and Cancer, Bethesda, Maryland, September 1991

Participants in the NCI symposium on Vitamin C and Cancer, Bethesda, Maryland, September 1991

At this same time, Pauling created a new position at LPISM for Rath, who was named the first Director of Cardiovascular Research. With this, Linus Jr. became even more concerned. Increasingly, he began to question his father’s administrative acumen and began taking steps to assume a more active role in the management of Institute, despite the fact that he lived in Hawaii.

Another big change was on the horizon as well. The city of Palo Alto was planning to change their zoning laws in an effort to increase residency, and informed LPISM that they had three years to find a new home. The Institute realized that the time allotted them was insufficient, and they began a campaign to delay the eviction.  Staff set up card tables in front of businesses, disbursing flyers and circulating a petition to keep LPISM where it was.

The positive response that they received from the locals was staggering and gave the Institute some measure of leverage in their conversations with the city. At one point, Steve Lawson was called before the city council, and one member said that she didn’t want to read in the New York Times that Palo Alto had kicked LPISM out of town. Eventually the council informed LPISM that the zoning law changes were still going to go through, but that the Institute would be granted more time to plan and relocate.

On the research front, after almost two years of marketing Pauling’s superconductor domestically with no leads, Rick Hicks decided to look abroad for a buyer. He contacted parties all over Europe and Asia, and one day a man showed up at the office to inquire about superconductor sales. He identified himself as an employee of the Central Intelligence Agency, which had taken an interest as to why LPISM was trying to sell this research internationally, especially in Japan, instead of on the U.S. market.

Hicks was away from the office at the time, but other employees were able to explain how he had tried unsuccessfully to sell it domestically first. Steve Lawson later recalled the experience as having been a jarring one. Unfortunately for LPISM, they also failed to sell the superconductor abroad and, due to an oversight, misplaced the paperwork required to pay the royalty fee needed to maintain the patent, which they lost as a result.


While this was going on, Pauling and Rath published a paper defining vitamin C deficiency as the major cause of cardiovascular disease. It immediately caused controversy, but the authors stood behind their work and continued on. Once again, concerns about Pauling’s infatuation with vitamin C began to resurge in the scientific community.

Another blow to the Institute’s fortunes was delivered on March 21, 1991, when Ewan Cameron died. His passing rocked the staff and morale plummeted. Shortly afterward, Pauling was diagnosed with prostate cancer and had to undergo surgery. On top of all of this, the fiscal report for the end of 1991 showed that LPISM was hundreds of thousands of dollars in debt. Workers remained loyal however, and numerous employees volunteered to suspend retirement contributions or work at reduced pay to keep the Institute afloat. Despite this, LPISM was still forced to cut their staff in half by early 1992.

Meanwhile, Pauling and Rath continued to promote vitamin C for cardiovascular disease prevention and treatment, and despite continuing doubts about their individual claims, they began to see more support as the medical community gradually realized that it had been underestimating the value of vitamin C for decades. As their work progressed, Rath’s connection to Pauling continued to grow.

In the spring of 1992, more change was clearly afoot when Emile Zuckerkandl’s contract with LPISM was not renewed. This was a controversial move, as Zuckerkandl was well-liked and respected by the staff. After his departure from LPISM, he founded his own institute, the Institute of Medical Molecular Sciences. He asked the Board of LPISM if he could lease space within LPISM for his new IMMS, a request that was granted.

Additionally, Zuckerkandl invited many of the LPISM staff who had been laid off to join IMMS. When he received news that Zuckerkandl was leaving, Rick Hicks, who by now was the Vice President for Financial Affairs, submitted his resignation as well. He had worked very closely with Zuckerkandl and wanted to follow him to other business ventures. The Board was surprised by Hicks’ resignation and the Institute didn’t want to lose its affiliation with him completely, so they elected him to the Board to keep him at least tangentially involved in LPISM. Happily, Hicks’ last act as an employee was to inform the Board that the estate of Carl L. Swadener had been bequeathed to the Institute and that it was valued at $2-3 million.

Linus Pauling Jr. was elected as the next Institute President, replacing Zuckerkandl. The organization that he took over was in grim shape, despite the windfall from the Swadener estate. As he assumed his new office, one of his top priorities was Matthias Rath. Amidst the recent shuffle, Linus Pauling had appointed Rath as Hicks’ replacement and at the same time the two had founded the Linus Pauling Heart Foundation, a separate and parallel organization to LPISM designed to focus on the Pauling-Rath cardiovascular disease research. These decisions were a source of concern to the Board and much of the staff, who were unsure if the Heart Foundation would be a competitor to the Institute, an arm of the Institute or a supporting organization to the Institute.


Overwhelmed by work, facing a serious illness and feeling his age, Linus Pauling officially retired from his leadership role at LPISM on July 23, 1992. In the wake of this announcement, the Board elected Steve Lawson as Executive Officer of the Institute, named Pauling its Research Director and Linus Pauling Jr. the Chairman of the Board. Linus Jr. immediately assumed a strong leadership role and, working closely with Lawson, aggressively pursued actions to solve the Institute’s numerous problems.

The two quickly decided that attaching LPISM to a university offered the best chance for its survival. At the same time, they realized that LPISM had become bloated and that they needed to pare back on the organization’s non-orthomolecular research, which had largely been created and expanded under Zuckerkandl’s leadership. While Linus Jr. and Lawson both agreed that the research was worthwhile, they also realized that the Institute simply lacked the funds to maintain it. Zuckerkandl had remained close to LPISM, and when almost all of his research programs were cut, he asked the researchers overseeing these programs to resign from LPISM and join IMMS, which many did.

While this was happening, tensions were mounting between Pauling, Linus Jr. and Matthias Rath. Pauling was informed that Rath had created an office for the Heart Foundation that was separate from LPISM, and that he had done so without permission and without even telling Pauling. He criticized Rath aloud for this decision, which only inflamed the situation.  From there, the speed with which the Pauling-Rath relationship soured was dramatic. In July, Rath was spending great amounts of time at Pauling’s home, and they frequently exchanged letters expressing a close friendship. By August they were hardly on speaking terms, and Rath was ultimately expelled from the Institute, asked to resign over a dispute involving intellectual property rights.

For all of the troubles of the 1980s, the ’90s were getting off to a rough start. The roller coaster ride would continue on in the time ahead, containing both the Institute’s darkest hours and its greatest triumphs.


The Departure of Art Robinson and Fallout from the First Mayo Clinic Study

Art Robinson, 1974.

Art Robinson, 1974.

[A history of the Linus Pauling Institute of Science and Medicine, Part 3 of 8]

By late 1978, the Linus Pauling Institute of Science and Medicine had reformed its fundraising strategy, an action which proved to be quite successful. As a result, for the first time in its five years of existence, LPISM was not struggling to keep its head above water.

This wave of good fortune carried with it unforeseen negative consequences. In particular, Rick Hicks and Art Robinson began to come into conflict over the best way to invest this sudden surplus. Robinson suggested that LPISM move to Oregon – which had recently announced “Linus Pauling Day” in honor of its native son – and build a campus of its own. The idea was not popular with many staff, most of whom did not want to leave the Bay Area.

At the same time, Robinson began cultivating ties with the Orthomolecular Research Institute in Santa Cruz, California, which was headed by Arnold Hunsberger. Linus Pauling was not pleased with this idea, as he felt Hunsberger’s research hypotheses to be off the mark. Pauling had also met Hunsberger and had said that his impression was “not a very favorable one.”

Robinson continued to press for closer ties between LPISM and ORI, a source of growing tension between him and Pauling. In particular, Pauling was angered when he learned that Robinson had begun to tailor experiments in accordance with Hunsberger’s ideas without first consulting Pauling. When confronted, Robinson defended his decision and redoubled his arguments for collaboration. Their relationship continued to sour and morale at LPISM plummeted as the tension between Pauling and Robinson mounted.

In June 1978, Pauling issued a memorandum to Robinson, ordering him to consult the Executive Committee – comprised of Pauling, Robinson, and Hicks – before making “any important decisions.” Robinson responded by immediately firing Hicks. Pauling responded in turn by overruling the termination and demanding Robinson’s resignation within thirty days. He then proceeded to issue a memorandum informing Institute staff that he had stripped Robinson of his position, and that the staff was to disregard all further instructions from Robinson. The next day, the staff arrived at work to find a second memorandum from Robinson, declaring that he was still the president, that neither Pauling nor Hicks had the authority to relieve him of his duties, and that he would not resign.

Pauling memorandum of July 10, 1978.

Pauling memorandum of July 10, 1978.

The Board of Trustees met in mid-July to try and settle the dispute. They decided to place Robinson on a thirty day leave of absence, empowered Pauling with all executive authority and told him to resolve the issue. On August 15, with Robinson’s leave expired, Pauling was elected President and Director of LPISM. On August 16, Pauling promptly informed Robinson that he was taking over all of Robinson’s research, Emile Zuckerkandl was being appointed Vice-Director, and that Robinson was fired.

Now that Robinson was gone, LPISM attempted to consolidate and return to normal. Pauling asked Steve Lawson to assume a portion of Robinson’s research agenda, a request to which Lawson consented. Over the course of 1978, Lawson had steadily become less involved with the financial arm of LPISM and more involved with its scientific work. Zuckerkandl also tasked Lawson with setting up a cell culture facility where the two would conduct research on the differences between primary and metastic cancer cells, as revealed by protein profiling. Lawson worked closely with UC-San Diego, University of Colorado, and SRI International. He was later joined on that project by Stewart McGuire, Eddy Metz, and Mark Peck, all fellow employees at LPISM.

Robinson, however, did not take his firing lightly and on August 25, LPISM was informed that Robinson was suing the organization for $25.5 million, alleging a breach of contract and unlawful termination among other charges. LPISM’s lawyers began gearing up for a serious legal battle, standing firm in their conviction that the Institute had done nothing wrong.

Meanwhile, the Institute’s vitamin C research continued on despite the added burden of the Robinson lawsuit. In early October 1978, Pauling convinced Ewan Cameron to accept a one-year appointment to LPISM while the two worked on a book about vitamin C and cancer. Additionally, Pauling, Cameron, Lawson, and their coworker Alan Sheets began an experiment to determine the effects of vitamin C on chemotherapeutic drugs. The research took the form of a toxicology experiment in which multiple groups of fish were subjected to chemotherapeutic agents in their water, after which various groups were given different amounts of vitamin C while the research team observed the results.

The year 1979 started with good news. LPISM was informed by Hoffmann-LaRoche, the world’s largest producer of vitamin C, that they had seen sales more than double during the 1970s, and they fully recognized that Pauling was the cause. As a thank you, they had decided to donate $100,000 a year to the Institute.

The happy days were not to last long. In April, LPISM received an advanced release of the results of the major Mayo Clinic study on the treatment of cancer with ascorbic acid. Its primary investigator, Charles Moertel, had concluded that vitamin C did absolutely nothing to help cancer patients. Pauling was stunned and immediately began writing to Moertel to discuss the study in detail.

Then, over the summer, Art Robinson filed six more charges against LPISM and Pauling, bringing the total number of suits to eight and the total requested damages to $67.4 million. The year-long and highly publicized suit was greatly hurting LPISM’s reputation, and the Institute noticed a subsequent decrease in the donor funds flowing their way.

"Vitamin C Fails as a Cancer Cure," New York Times, September 30, 1979.

“Vitamin C Fails as a Cancer Cure,” New York Times, September 30, 1979.

Things then went from bad to worse when, on September 27, the New York Times published the Mayo Clinic study, definitively stating its conclusion that vitamin C was useless in treating cancer. Pauling immediately responded by pointing out that the patients involved in the test were undergoing cytotoxic chemotherapy, which he felt crippled their immune system. He also asserted that the trial was not conducted for long enough to develop accurate results.

Pauling's response to the New York Times article, October 24, 1979.

Pauling’s response to the New York Times article, October 24, 1979.

Charles Moertel returned fire, defending his results and questioning Pauling, implying that he was fanatical in his zeal for vitamin C and refused to acknowledge the truth. Pauling and Moertel began exchanging volleys in public, writing articles and giving interviews that attacked the research and competence of the other. Unfortunately for Pauling, he took the worst of it, as many people began to agree with Moertel, thinking Pauling to be too enamored with vitamin C to see any negatives. Funding plummeted as donations shrank and LPISM began finding large numbers of grants rejected outright with no chance for an appeal.

Pauling refused to give up. Shortly after the New York Times article was released, he and Cameron published their book, Cancer and Vitamin C. Pauling personally bought 16,000 copies of the publication and mailed them to every member of Congress and to countless other physicians and researchers. This action helped Pauling’s cause significantly as many of the recipients read the book, or at least glanced through it. And even those recipients who didn’t read the text were made more aware of Pauling and his research. Likewise, in the marketplace the book sold well despite the bad reception it received from professional reviewers – the public seemed interested in Pauling and Cameron’s ideas.

In light of this, National Cancer Institute head Vincent DeVita agreed to a second round of trials. However, in doing so DeVita once again chose the Mayo Clinic to host the trials and chose Moertel to lead them. Pauling was furious with these decisions, an understandable point of view considering that he and Moertel had spent the past few months publicly accusing one other of being incompetent.  Pauling was also now without his co-author: their book completed, Ewan Cameron returned to Scotland to fulfill his duties at Vale of Leven Hospital. Before leaving, he was appointed a Research Professor at LPISM for a period of five years.

With a new decade approaching, the easier times of the mid-1970s were clearly gone and by early 1980 the future was once again uncertain. While the tensions evident during the Art Robinson era were now history, his lawsuits and the Mayo Clinic trials severely detracted from the future prospects of LPISM. Unfortunately for the Institute and Linus Pauling, their immediate future was not going to be a happy one.

Important New Hires and Battles with the National Cancer Institute

Art Robinson and Rick Hicks with LPISM visitors, 1977.

Art Robinson and Rick Hicks with LPISM visitors, 1977.

[A history of the Linus Pauling Institute of Science and Medicine, Part 2 of 8]

By the end of 1975, the Linus Pauling Institute of Science and Medicine found itself teetering on the brink of financial collapse. Linus Pauling was donating his entire salary and even personal funds from his bank account to LPISM, and every employee had taken meaningful pay cuts. Everyone involved realized that the organization could not hope to succeed if business was to continue as usual.

An important change came in March 1976, when Richard Hicks was hired to help with fundraising. This move proved to be a windfall as Hicks interjected new energy and ideas into the search for additional income. One of the Institute’s most important employees for many years, Hicks rather quickly utilized his talents to help alleviate the extreme financial problems of 1975.  With Hicks on board, the Institute was only treading water, but the imminent threat of drowning had lessened.

Later in 1976, Pauling published Vitamin C, the Common Cold, and the Flu, an updated version of his earlier book Vitamin C and the Common Cold. The book sold reasonably well and managed to bring some much needed cash in to LPISM, though not as much as the organization had hoped. Additionally, Ewan Cameron and Pauling published another paper on vitamin C and cancer, which stated that terminal cancer patients lived longer and enjoyed a higher quality of life when given supplemental vitamin C.


Just as conditions were starting to improve, the Institute suffered another major setback when investigators from the National Cancer Institute visited LPISM to check on the progress of its hairless mice skin cancer study. In their report the investigators frowned upon the Institute’s tiny staff, what it deemed to be bad management by its administrators, and Pauling’s frequent absences. Their harsh judgement helped to “sink the Institute’s future grant requests” for many years afterward, thus forcing LPISM to redouble its efforts to secure new sources of private funding.

On the research front, Art Robinson began working with Kaiser-Permanente to set up a national sample bank with tens of thousands of blood and urine samples that LPISM could utilize for better research. The collaboration was moving along smoothly until Kaiser realized that the bill for the project would be in the neighborhood of $5.8 million, at which point Kaiser decided to scrap the deal in a most expedient fashion. In 1977, a year after negotiations had started, Robinson was informed that the plan was rejected because it was too ambitious and vague.

Robinson wasn’t the only one receiving that response. Pauling had been seeking grant funding from the NCI from the moment that its investigators’ report had been released. He reasoned that if the NCI was complaining that LPISM was too small, then they should give him more money to expand. By 1977 he had been turned down four times by the organization, each time under the auspices of his proposals being too ambitious and vague.

In light of the bad press that accompanied the NCI’s dismissals, Pauling sent copies of his proposals and rejection letters to twenty-four members of Congress, including the senators heading the committees on health and nutrition, Ted Kennedy and George McGovern respectively. He received no response, and in turn asked his lawyer if he could sue the NCI for bias. His lawyer advised him that there was no legal precedent for such a case, and that the chances of successfully suing a federal agency were “less than slim.”

Linus Pauling and Emile Zuckerkandl, 1986.

Linus Pauling and Emile Zuckerkandl, 1986.

In early 1977, LPISM hired two people, both of whom ended up making major contributions to the Institute. First they hired Emile Zuckerkandl to lead their research on genetics. Zuckerkandl brought a different type of personality to the Institute. He and his family had fled Austria shortly before the onset of World War II, as they were wealthy and Jewish. In fleeing they had managed to bring with them some of their rare artwork collection, which Zuckerkandl would show to his coworkers at LPISM from time to time. A renowned scientist, Zuckerkandl had worked previously with Pauling at Caltech, collaborating and co-developing a theory of molecular evolution.

The second person of note to be hired was Stephen Lawson, who was brought on board to assist with direct-mail solicitations for fundraising. Lawson’ s position was very much at the entry level.  When he was hired he was not associated with the Institute in any way, and his only concrete knowledge of Linus Pauling harkened back to a chapter during his student days at Stanford University, when he saw Pauling protesting the firing of a tenured instructor.

About this time, the NCI also brought someone in: a new head named Vincent DeVita. He was more open-minded about Pauling and his vitamin C work, and was aware of how much public support Pauling had accumulated. As a result he consented to speak with Pauling and, after a multi-hour meeting, agreed to set up a conclusive clinical trial on vitamin C and cancer. When asked about the apparent reversal of the NCI’s opinion of Pauling’s work, DeVita responded that Pauling “can be a very persuasive man.” By March DeVita had arranged for the trials to be carried out at the prestigious Mayo Clinic, headed by the esteemed Dr. Charles G. Moertel. Pauling and DeVita met again in April to discuss the details of how the trial would be conducted.

Vincent DeVita, 1999.

Vincent DeVita, 1999.

On the eve of the Moertel study, circumstances appeared to be improving across the board for the Institute. With more apparent support for his research, Pauling expanded his program and in 1977 began a new series of tests designed to determine the effect of vitamins on tumor growth. The tests utilized 600 hairless mice as subjects. Additionally, LPISM managed to acquire enough funds to hire a professional direct-mail company for fundraising, and was able to place a number of successful advertisements in major financial periodicals including Barron’s and the Wall Street Journal. With these changes, LPISM saw a hefty boost in its incoming funds.

Buoyed by the success of the direct-mail strategy, LPISM began focusing its fundraising on this type of marketing. The move proved to be very effective and non-governmental donations increased from 50% of LPISM’s funding to 85% -the organization received almost $1.5 million in private donations in 1978 alone. For the first time in its short history, LPISM wasn’t suffering from financial hardships.

Clarifying Three Widespread Quotes

When we find ourselves with a few spare moments, one of our favorite pastimes is conducting Google Blogsearch queries for the term “Linus Pauling.”  Typically we come across a few of the more recent posts that we ourselves have published, catch up with the latest news from The Linus Pauling Quartet and sometimes unearth interesting bits of information that spur new ideas for the PaulingBlog.

One does not have to search for too long, however, before finding one of three quotes that have spread rather dramatically across the internet.  One of these quotes was definitely uttered by Pauling, but is often imperfectly reproduced.  A second quote was actually published, but we have our doubts as to whether or not Pauling really did say it.  The third quote, we and others feel, is likely a fabrication.

Yes: On Having Good Ideas

Pauling delighted in recounting a specific quote on his “method” for having good ideas.  The quote shows up in many forms at various spots on the web, but is probably best recited as follows:

The best way to have good ideas is to have lots of ideas and throw away the bad ones.

The provenance of this famous quote is traced to a letter written to Pauling by a former graduate student, David Harker, in commemoration of Pauling’s sixtieth birthday.  Here’s the urtext:

Excerpt from a letter by David Harker to Linus Pauling, February 20, 1961.

Excerpt from a letter by David Harker to Linus Pauling, February 20, 1961.

Listen: Pauling recounts the circumstances of this quote:

Maybe: On Cancer Research

“Everyone should know that most cancer research is largely a fraud, and that the major cancer research organizations are derelict in their duties to the people who support them.”

Google has indexed 547 static webpages that include some version of this quote, attributed to Linus Pauling.  Only one of these 547 pages includes a citation: Outrage! For Those Opposed to Animal Abuse. (Tonbridge, Kent England) 47, October/November 1986.  The staff at Animal Aid, which published this issue of Outrage!, kindly provided us with a scan of the page on which this quote appears — see the lower left-hand side:

pg. 14

Outrage! (Oct/Nov 1986): pg. 14

The first detail that pops out to us is that there is no citation provided for the quote.  It’s pretty clear too, that the quote was not given by Pauling as an exclusive to Outrage! Moreover — and most importantly — it seems unlikely to us that Pauling would paint with such a clumsy brush in recounting his feelings about cancer research.

The background to the cancer research circumstance is fascinating but too complex for us to detail here. (Evelleen Richards’ tremendous Vitamin C and Cancer: Medicine or Politics? is highly recommended for those interested in the whole story)  For our purposes, it is sufficient to say that Pauling took considerable umbrage with a series of trials conducted by the Mayo Clinic, first in 1979 and later in 1985, that purported to refute his and Ewan Cameron‘s work on the potential for treating cancer with large amounts of ascorbic acid. (A bit more background is here and here.) One of Pauling’s major complaints was that the Mayo Clinic had misrepresented its trial methods in a manner that biased the data toward its eventual conclusion.  In her book, Richards includes the text of a slide that Pauling often used in his post-Mayo lectures on vitamin C and cancer:

The Mayo article is misleading and dishonest.  It might be described as fraudulent.  It purported to be a repetition of Dr. Cameron’s study, but it was greatly different, in a way that the Mayo Clinic investigators succeeded in hiding from the readers of their paper.

Clearly Pauling was deeply upset about the Mayo trials and their conclusions — his anger on this matter is well-documented in the Pauling archive — and he obviously wasn’t against describing the Mayo work as “fraudulent.”  However, his extending that description to “most cancer research” strikes us as being out of character.  Pauling was a very clear thinker and a careful writer, and it seems to us that his feelings about cancer research, circa 1986, are more likely summed up by these extracts from his book How to Live Longer and Feel Better

Despite the great amount of money and effort expended in the study of cancer, progress during the last twenty-five years has been slow.  A significant increase in survival time after diagnosis was achieved about thirty years ago, largely through improvements in the techniques of surgery and anesthesia.  During the last twenty-five years some improvement in treatment of certain kinds of cancer has been achieved, mainly through the use of high-energy radiation and chemotherapy, but for most kinds of cancer there has been essentially no decrease in either incidence or length of time of survival after diagnosis, and it has become evident that some new ideas are needed, if greater control over this scourge is to be achieved.

Critical?  For sure.  But hardly incendiary. None of this, of course, is proof that Pauling, in a fit of pique, didn’t one day lump most cancer research under the “Fraud” heading.  Our feeling is that it is unlikely.  But even if he did, the calmer and more balanced 1986 quote is surely more indicative of his true feelings on the matter.

Probably Not: On the Importance of Minerals

“You can trace every sickness, every disease, and every ailment to a mineral deficiency.”

This one shows up on roughly 1,500 web pages and is uniformly uncited.  Importantly, most of the 1,500 sites on which the text is used are attempting to sell a product. In the Spring/Summer 2003 edition of their newsletter, the Linus Pauling Institute staff directly addressed the dubious nature of these thoughts on minerals.

A statement purportedly attributed to Linus Pauling has proliferated on the Internet, often in association with the sale of mineral supplements. The alleged quote is usually akin to “You can trace every sickness, every disease, and every ailment to a mineral deficiency.” We are reasonably certain that Pauling never made such a statement for the obvious reason that it is untrue. Pauling was interested in the health effects of micronutrients, especially vitamin C, the vitamin that absorbed his interest for almost thirty years. Throughout his career, Pauling used x-ray diffraction to elucidate the molecular structure of many inorganic substances, such as minerals, and organic substances like proteins. If he had been particularly interested in the health benefits of minerals, he would have focused his research in this direction. There is no evidence in the published literature that he did so.

Indeed, while Pauling does recommend taking a mineral supplement every day as part of his “Regimen for Better Health” (How to Live Longer and Feel Better, p. 9) he specifically warns against overdoing it (p. 12), noting that

The essential minerals differ from the vitamins in that overdoses of minerals may be harmful.  Do not increase your vitamin intake by taking a large number of vitamin-mineral tablets.  Limit your mineral intake to the recommended amounts.

This from a guy who was taking 18 grams of vitamin C at the time that he was authoring How to Live Longer…

We feel reasonably confident in our research on the items discussed in this post.  However, if anyone can provide definitive proof for either the cancer research or minerals quotes, please do let us know and we’ll promise to devote a future blog post to further clarification of the matter.